Mentor almost free of urology
This article was originally published in The Gray Sheet
Executive Summary
Firm announces definitive agreement to sell its Surgical Urology and Clinical and Consumer Healthcare divisions to Coloplast for $463 mil. on May 17. The transaction will enable Mentor to focus on the development of its aesthetics business (1"The Gray Sheet" April 3, 2006, p. 7). Mentor also reported that it has initiated a four-month Phase 1 study of its botulinum toxin type A product to treat pain associated with adult onset spasmodic torticollis/cervical dystonia...
You may also be interested in...
Mentor Finds Prospective Buyer For Urology Business In Coloplast
Mentor signaled March 27 that it has found a buyer for its urology business, furthering its shift to aesthetics medicine
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.